Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Synairgen PLC

+ Add to Watchlist

SNG:LN

34.250 GBp 0.250 0.74%

As of 11:30:00 ET on 04/24/2015.

Snapshot for Synairgen PLC (SNG)

Open: 34.000 Day's Range: 34.000 - 34.250 Volume: 242,700
Previous Close: 34.000 52wk Range: 26.500 - 86.000 1-Yr Rtn: -34.76%

Stock Chart for SNG

No chart data available.
  • SNG:LN 34.250
  • 1D
  • 1M
  • 1Y
34.000
Interactive SNG Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SNG

Current P/E Ratio (ttm) 19.6275
Estimated P/E(12/2015) -
Relative P/E vs. UKX 0.8087
Earnings Per Share (GBP) (ttm) 0.0175
Est. EPS (GBP) (12/2015) -0.0460
Est. PEG Ratio -
Market Cap (M GBP) 31.28
Shares Outstanding (M) 91.32
30 Day Average Volume 107,210
Price/Book (mrq) 3.3145
Price/Sale (ttm) 6.1692
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 09/25/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SNG

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for SNG

Synairgen PLC is a drug research company. The Company researches treatments for asthma and chronic obstructive pulmonary disease. Synairgen uses an in vitro cell model of human diseases.

Richard James MarsdenCEO/Managing DirectorJohn Christopher WardFinance Director/Secretary
Phillip MonkChief Scientific Officer
More Company Profile & Key Executives for SNG

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil